Results of Operations and Financial Condition. On August 13, 2026, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing business updates and second quarter 2026 financial results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…

Chief Business and Financial Officer, principal financial officer, principal accounting officer and secretary — Jeffrey Rona: Mr. Rona mutually agreed to transition from his roles, resulting in a genuine departure.

Director — Anna Greka, M.D., Ph.D.: Dr. Anna Greka was appointed as a Class III director and joined the Compensation Committee and Science and Technology Committee.

Results of Operations and Financial Condition. On May 12, 2026, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing business updates and first quarter 2026 financial results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934…

Other Events. On April 17, 2026, the Series A Warrants (the “Series A Warrants”) issued by Ovid Therapeutics Inc. (the “Company”) in connection with its October 2025 private placement expired. The aggregate number of common shares underlying the Series A Warrants was 38,481,325, and investors elected to exercise the warrants into 33,597,860 shares of the Company’s common stock for $1.40 per share and 4,883,464 pre-funded warrants for $1.399 per share, resulting in gross proceeds to the Compan…

Results of Operations and Financial Condition. On March 18, 2026, the Company issued a press release announcing new OV329 data and indication expansion, Phase 1 clearance for OV4071, and fourth quarter and full year 2025 financial results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Secti…

Unregistered Sales of Equity Securities. The information contained in

Entry into a Material Definitive Agreement. Securities Purchase Agreement On March 17, 2026, Ovid Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate of 19,154,321 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $2.01 per share and, in lieu of Common Stock, p…

Results of Operations and Financial Condition. On November 12, 2025, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing a planned leadership succession, business updates and third quarter 2025 financial results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18…

Chief Executive Officer — Margaret “Meg” Alexander: Ms. Alexander was promoted to CEO, succeeding Dr. Jeremy M. Levin.

Unregistered Sales of Equity Securities. The information contained in

Entry into a Material Definitive Agreement. Securities Purchase Agreement On October 2, 2025, Ovid Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate of (i) 57,722 shares of its Series B convertible preferred stock, par value $0.001 per share (the “Series B Preferred Stock”), (ii) Series A warrants (the “Series A Warran…

Results of Operations and Financial Condition. On August 13, 2025, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing business updates and second quarter 2025 financial results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed on a Current Report on Form 8-K filed by the Company on February 13, 2025, the Company received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) on February 10, 2025 notifying the Company that the average closing bid price of the Company’s shares of common stock was below the minimum closing bid price of $1.00 per sh…

Results of Operations and Financial Condition. On May 13, 2025, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing Business Update, First Quarter 2025 Financial Results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as…

Results of Operations and Financial Condition. On March 11, 2025, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing Business Updates and Fourth Quarter and Full Year 2024 Financial Results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exc…

Director — Stelios Papadopoulos, Ph.D.: Dr. Stelios Papadopoulos was appointed as a Class I director and joined the Audit Committee and Compensation Committee.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average closing bid price of the Company’s shares of common stock was below the minimum closing bid price of $1.00 per share during the last 31 consecutive trading days (the “Notice…

Results of Operations and Financial Condition. On November 12, 2024, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing Business Update, Third Quarter 2024 Financial Results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 193…

President and Chief Operating Officer (COO) — Margaret “Meg” Alexander: Ms. Alexander was promoted to President and COO with significant responsibilities and equity incentives.

Results of Operations and Financial Condition. On August 13, 2024, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing Business Update, Second Quarter 2024 Financial Results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934…

General Counsel, Chief Compliance Officer, Corporate Secretary — Thomas Perone: Mr. Perone is departing from his roles due to a workforce reduction.

Regulation FD Disclosure. Cash Sufficiency Forecast The Company believes that its cash runway will be sufficient to fund its operations into the first half of 2026, which reflects the estimated cost savings from the workforce reduction. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements, including, but not limited to, statements related to the results of the workforce reduction, any estimated charges associated with the workforce reduction and expec…

Departures are associated with a workforce reduction.

Costs Associated with Exit or Disposal Activities. On June 27, 2024, the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”) approved a reduction of the Company’s workforce to prioritize its programs and extend its cash runway. The Company will reduce its workforce by 17 people, or approximately 43% of the Company’s existing headcount, to preserve cash resources. The workforce reduction was communicated to a majority of the impacted employees on June 28, 2024 and has an…